IMCR
Price
$32.60
Change
+$2.76 (+9.25%)
Updated
Oct 20 closing price
Capitalization
1.68B
22 days until earnings call
Intraday BUY SELL Signals
PMCB
Price
$0.34
Change
-$0.00 (-0.00%)
Updated
Oct 20 closing price
Capitalization
3.67M
57 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IMCR vs PMCB

IMCR vs PMCB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
IMCR vs. PMCB commentary
Oct 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMCR is a StrongBuy and PMCB is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for IMCR with price predictions
Oct 19, 2026

IMCR's RSI Oscillator ascends from oversold territory

The RSI Oscillator for IMCR moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 23 of the 27 cases the stock moved higher. This puts the odds of a move higher at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 59 cases where IMCR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.

The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on IMCR as a result. In 58 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.

The Moving Average Convergence Divergence (MACD) for IMCR just turned positive on October 15, 2026. Looking at past instances where IMCR's MACD turned positive, the stock continued to rise in 37 of 47 cases over the following month. The odds of a continued upward trend are 79%.

Following a +5.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMCR advanced for three days, in 219 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

IMCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day moving average for IMCR crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for IMCR entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.999) is normal, around the industry mean (2.978). IMCR has a moderately low P/E Ratio (-90.556) as compared to the industry average of (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (3.791) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. IMCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for PMCB with price predictions
Oct 20, 2026

PMCB's Indicator enters downward trend

The Aroon Indicator for PMCB entered a downward trend on September 21, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 266 similar instances where the Aroon Indicator formed such a pattern. In 238 of the 266 cases the stock moved lower. This puts the odds of a downward move at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PMCB as a result. In 103 of 121 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

The Moving Average Convergence Divergence Histogram (MACD) for PMCB turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In 45 of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PMCB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

PMCB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.132) is normal, around the industry mean (3.009). P/E Ratio (-0.165) is within average values for comparable stocks, (-1.027). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. PMCB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PMCB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
PMCB: Fundamental Ratings
PMCB
OUTLOOK RATING
1..100
57
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
90
P/E GROWTH RATING
1..100
97
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
IMCRPMCB
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 1 day ago
77%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 1 day ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 1 day ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 6 days ago
74%
N/A
Declines
ODDS (%)
Bearish Trend 8 days ago
82%
Bearish Trend 2 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 1 day ago
89%
COMPARISON
Comparison
Oct 21, 2026
Stock price -- (IMCR: $32.60 vs. PMCB: $0.34)
Brand notoriety: IMCR and PMCB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMCR: 242% vs. PMCB: 11%
Market capitalization -- IMCR: $1.68B vs. PMCB: $3.67M
IMCR [@Biotechnology] is valued at $1.68B. PMCB’s [@Biotechnology] market capitalization is $3.67M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.44B. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMCR’s FA Score shows that 2 FA rating(s) are green while PMCB’s FA Score has 0 green FA rating(s).

  • IMCR’s FA Score: 2 green, 3 red.
  • PMCB’s FA Score: 0 green, 5 red.
According to our system of comparison, IMCR is a better buy in the long-term than PMCB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMCR’s TA Score shows that 6 TA indicator(s) are bullish while PMCB’s TA Score has 3 bullish TA indicator(s).

  • IMCR’s TA Score: 6 bullish, 3 bearish.
  • PMCB’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, IMCR is a better buy in the short-term than PMCB.

Price Growth

IMCR (@Biotechnology) experienced а +17.18% price change this week, while PMCB (@Biotechnology) price change was -3.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.45%. For the same industry, the average monthly price growth was -16.03%, and the average quarterly price growth was -14.84%.

Reported Earning Dates

IMCR is expected to report earnings on Nov 11, 2026.

PMCB is expected to report earnings on Dec 16, 2026.

Industries' Descriptions

@Biotechnology (-0.45% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
IMCR
Daily Signal:
Gain/Loss:
PMCB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ARL16.520.79
+5.02%
American Realty Investors
LVO2.310.07
+2.90%
LiveOne Inc
SXT135.222.08
+1.56%
Sensient Technology Corp
ING32.960.14
+0.43%
ING Groep NV
WOLF23.50-0.64
-2.65%
Wolfspeed Inc

IMCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMCR has been loosely correlated with SANA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if IMCR jumps, then SANA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMCR
1D Price
Change %
IMCR100%
+9.25%
SANA - IMCR
44%
Loosely correlated
+2.61%
NRIX - IMCR
43%
Loosely correlated
+4.69%
SLDB - IMCR
43%
Loosely correlated
+8.11%
XNCR - IMCR
42%
Loosely correlated
+7.55%
VIR - IMCR
42%
Loosely correlated
+5.19%
More